<DOC>
	<DOCNO>NCT01754272</DOCNO>
	<brief_summary>This follow-on study VELOUR trial ( NCT00561470 ) . The aim study acquire archive colorectal cancer metastasize tissue tumour block patient participate VELOUR study . These sample analyse find proteins marker represent individual may respond treatment . The identification marker may help provide personalised effective treatment program patient similar condition future .</brief_summary>
	<brief_title>A Non-Interventional Follow-Up VELOUR Study - Translational Research</brief_title>
	<detailed_description>The VELOUR trial ( NCT00561470 ) demonstrate efficacy aflibercept second line treatment combination fluorouracil , leucovorin , irinotecan ( FOLFIRI ) metastatic colorectal cancer ( mCRC ) patient refractory first line oxaliplatin base chemotherapy regimen ( Van Cutsem E. , JCO 30 ( 2012 ) : pp3499-3506 ) . The FDA approve Aflibercept ( Zaltrap ) treatment metastatic colorectal cancer combination FOLFIRI August 3rd 2012 European Medical Agency ( EMEA ) November 15th 2012 . While VELOUR study confirm benefit use aflibercept combination FOLFIRI , availability biomarkers accurately predict patient respond combination would improve clinical utility drug . The molecular profiling Formaldehyde fix paraffin embed ( FFPE ) clinical tumor sample serial plasma sample obtain patient involve VELOUR study subsequent analysis molecular clinical data would provide invaluable opportunity discover potentially validate biomarkers . As block collect part VELOUR trial , protocol deal primarily step take gain ethics consent participate country block source acquire , finally deposit biobank situate KULeuven . A VELOUR Translational Research Consortium ( VTRC ) form Catholic University Leuven ( KULeuven ) Almac Diagnostics realisation study . The number block available base surgical list hold trial estimate 1030 ( 84 % complete trial cohort ) profile viewpoint calculate minimum number block acceptable processing biomarker identification / validation 500 . Due specific interest angiogenesis , VTRC consortium aim source block tumor surround stromal tissue macro-dissected aim generate data tumor surround angiogenic stroma . The project generate gene expression , immunohistochemistry ( IHC ) mutational data sample . In addition single nucleotide polymorphism ( SNP ) data generate non-tumor tissue , focus polymorphism demonstrate association disease response outcome therapy . Pre-processing silico evaluation data generate support outcome objective study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients participate VELOUR trial Patients participate VELOUR trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>mCRC</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>translational research</keyword>
	<keyword>retrospective</keyword>
	<keyword>noninterventional</keyword>
	<keyword>biomarkers</keyword>
	<keyword>angiogenesis</keyword>
</DOC>